BMY — BRISTOL MYERS SQUIBB CO
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Dividends
Measured signals that fired on BMY
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-03 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-03 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-27 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-17 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-29 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-01 | Massacesi Cristian EVP,Chief Med Offr,Head of Dev | Shares withheld for tax | 26.2K | 65.31 | 1.7M |
| 2026-08-01 | Gallman Cari EVP, General Counsel | Shares withheld for tax | 543 | 65.31 | 35.5K |
| 2026-08-01 | Massacesi Cristian EVP,Chief Med Offr,Head of Dev | Option exercise | 51.2K | 0.00 | 0 |
| 2026-08-01 | Gallman Cari EVP, General Counsel | Option exercise | 1.1K | 0.00 | 0 |
| 2026-06-15 | Haller Julia A Director | Option exercise | 20.5K | 53.76 | 1.1M |
| 2026-06-03 | Short Bartie Wendy EVP, Corporate Affairs | Shares withheld for tax | 3.9K | 54.72 | 212.1K |
| 2026-06-03 | Short Bartie Wendy EVP, Corporate Affairs | Option exercise | 8.0K | 0.00 | 0 |
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Shares withheld for tax | 599 | 58.22 | 34.9K |
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Other Acquisition/Disposition | 203 | 0.00 | 0 |
| 2026-05-01 | Lenkowsky Adam EVP, Chief Commercial Officer | Option exercise | 1.4K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 10.4B | 171.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.0B | 132.3M |
| STATE STREET CORP | 6.0B | 98.6M |
| JPMORGAN CHASE & CO | 5.5B | 92.5M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3.7B | 61.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.3B | 55.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8B | 46.2M |
| BANK OF AMERICA CORP /DE/ | 2.0B | 32.6M |
| AQR CAPITAL MANAGEMENT LLC | 1.8B | 29.6M |
| MORGAN STANLEY | 1.8B | 29.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G | 2026-08-07 | — | on EDGAR ↗ |
| 4 | 2026-08-04 | 2026-08-01 | on EDGAR ↗ |
| 4 | 2026-08-04 | 2026-08-01 | on EDGAR ↗ |
| 10-Q | 2026-07-30 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-07-30 | 2026-07-30 | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-06-30 | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-06-30 | on EDGAR ↗ |
| 4 | 2026-07-02 | 2026-06-30 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Bristol-Myers Squibb stock trades near guidance-implied value as Q2 beat supports 2026 outlook - Ad-hoc-news.de · 2026-08-22 · Ad-hoc-news.de
- Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma · 2026-08-19
- AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? · 2026-08-14
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? · 2026-08-14
- US FDA approves Bristol Myers' blood cancer treatment - Reuters · 2026-08-13 · Reuters
- Lawsuit against Bristol Myers over delayed cancer drug is revived · 2026-08-13
Others in Healthcare
Ask the AI about BMY
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →